EDGEWISE THERAP. DL-,0001

Servier has completed the acquisition of Edgewise’s muscular dystrophy unit, paying $1.55 billion upfront and up to $1.1 billion in milestones. The deal includes sevasemten, an oral myosin inhibitor in late‑stage development that is being studied in a registration‑relevant cohort study for Becker muscular dystrophy and in phase‑2 studies for Duchenne muscular dystrophy. The transaction is approved by regulators and is intended to strengthen Servier’s pipeline for rare neurological diseases. » Więcej na de.investing.com

Edgewise has completed the sale of sevasemten and its muscular dystrophy business to Servier. The deal includes a $1.55 billion upfront payment plus up to $1.1 billion in milestones; Servier acquires all rights and offered affected employees a transition. Edgewise plans to use the upfront payment to fully fund development of EDG-7500 and will focus going forward on cardiovascular programs with EDG-7500, EDG-15400 and EDG-003. Sevasemten is in late-stage clinical trials for Becker and Duchenne muscular dystrophy and holds orphan-drug and Fast Track status from the FDA; initial readouts from a registrational study are expected in Q4 2026. » Więcej na de.investing.com

Edgewise Therapeutics shares rose to a record high of $43.96 and are currently trading around $44.17, implying a market capitalization of about $4.66 billion. Analysts repeatedly raised price targets (including RBC $59, Truist $52, Leerink $50, Guggenheim $51) following positive Phase‑2/12‑week data for EDG‑7500 and CIRRUS‑HCM. The planned sale of the Duchenne muscular dystrophy unit to Servier for $1.55 billion was also announced. However, InvestingPro data indicate the stock may be overvalued relative to its fair value. » Więcej na de.investing.com